Physician profile
Stephanie Elyse Smith
NPI 1720563596
$8,557.72
in general payments reported to CMS, 2019-2025
31 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,374 · 2022: $1,872 · 2023: $1,508 · 2024: $1,514 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,311.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,678.38 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,531.02 | 2021-2025 | |
| Genzyme Corporation | $645.48 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $621.26 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Intercept Pharmaceuticals, INC. | $527.87 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $362.72 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $347.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $313.43 | 2023-2025 | Epclusa |
| Ardelyx, INC. | $279.47 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $268.21 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $210.64 | 2021-2024 | Linzess |
| Aimmune Therapeutics, INC. | $209.15 | 2025 | Zenpep |
| Celgene Corporation | $204.20 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $186.31 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $179.28 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $135.73 | 2022-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $109.51 | 2021-2024 | Dificid |
| Mallinckrodt Hospital Products INC. | $100.25 | 2022-2024 | Terlivaz |
| Braintree Laboratories, INC. | $100.22 | 2022-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $93.47 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $85.77 | 2021 | |
| Daiichi Sankyo INC. | $72.41 | 2022-2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $59.20 | 2025 | Iqirvo |
| Intra-Sana Laboratories | $56.32 | 2022 | |
| Celltrion USA INC. | $44.88 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $43.61 | 2023-2024 | Omvoh |
| Astrazeneca Pharmaceuticals LP | $19.96 | 2024 | Andexxa |
| Intuitive Surgical, INC. | $19.84 | 2022 | |
| Boston Scientific Corporation | $19.12 | 2025 | Watchman Flx |
| Fresenius Kabi USA, LLC | $17.85 | 2023 | Idacio |
| Amag Pharmaceuticals, INC. | $14.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.